{"id":4471,"date":"2018-09-04T11:27:08","date_gmt":"2018-09-04T11:27:08","guid":{"rendered":"https:\/\/europeanvenousforum.org\/?page_id=4471"},"modified":"2018-09-04T11:33:28","modified_gmt":"2018-09-04T11:33:28","slug":"19th-evf-athens-industry-symposia","status":"publish","type":"page","link":"https:\/\/europeanvenousforum.org\/index.php\/19th-evf-athens-industry-symposia\/","title":{"rendered":"19th EVF Athens Industry Symposia"},"content":{"rendered":"<h2 style=\"text-align: center;\"><span style=\"color: #003366;\"><strong>Industry Sponsored Sessions<\/strong><\/span><\/h2>\n<p>&nbsp;<\/p>\n<ul>\n<li style=\"text-align: center;\">\n<h3><span style=\"color: #800000;\"><strong>Tripartite Meeting<\/strong><\/span><\/h3>\n<\/li>\n<li style=\"text-align: center;\"><span style=\"color: #808080;\">19<sup>th<\/sup> Meeting of the European Venous Forum<\/span><\/li>\n<li style=\"text-align: center;\"><span style=\"color: #808080;\">9<sup>th<\/sup> Annual Meeting of the Balkan Venous Forum<\/span><\/li>\n<li style=\"text-align: center;\"><span style=\"color: #808080;\">Hellenic Phlebological Society Summit<\/span><\/li>\n<li style=\"text-align: center;\"><\/li>\n<li style=\"text-align: center;\"><span style=\"color: #808080;\">Olympia Hall, Royal Olympic Hotel, Athens, Greece<\/span><\/li>\n<li style=\"text-align: center;\"><span style=\"color: #808080;\">28-30 June 2018<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong><span style=\"color: #800000;\">THURSDAY 28 JUNE 2018<\/span><\/strong><\/p>\n<table style=\"height: 440px;\" width=\"672\">\n<tbody>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.00-12.00<\/span><\/td>\n<td width=\"558\"><span style=\"color: #808080;\">Industry Session supported by a grant from Pierre Fabre<\/span><\/p>\n<p><span style=\"color: #808080;\"><strong>CVD: From Symptoms to Microcirculation<\/strong><\/span><\/p>\n<p><em><span style=\"color: #808080;\">Chair: Andrew Nicolaides (Cyprus)<\/span><\/em><\/td>\n<\/tr>\n<tr>\n<td width=\"119\">\n<p style=\"text-align: center;\"><span style=\"color: #800000;\">11.00-11.20<\/span><\/p>\n<\/td>\n<td width=\"558\"><span style=\"color: #808080;\">What symptoms mean and how they influence our choice of investigations.\u00a0 <em>Marianne De Maeseneer (Belgium)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"119\">\n<p style=\"text-align: center;\"><span style=\"color: #800000;\">11.20-11.40<\/span><\/p>\n<\/td>\n<td width=\"558\"><span style=\"color: #808080;\">Is there a link between symptoms and microcirculation alternations? <em>Bernardo Barros (Brazil)<\/em><\/span><\/p>\n<ul>\n<li><span style=\"color: #808080;\">CEAP classification and capillaries morphology<\/span><\/li>\n<li><span style=\"color: #808080;\">Can capillaries and venules impairment explain symptoms in Cos patients?<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td width=\"119\">\n<p style=\"text-align: center;\"><span style=\"color: #800000;\">11.40-12.00<\/span><\/p>\n<\/td>\n<td width=\"558\">\u00a0<span style=\"color: #808080;\">How to choose the right VAD for the right patient, based on updated EVF Guidelines? <em>Stavros Kakkos (Greece)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"119\">&nbsp;<\/p>\n<p>&nbsp;<\/td>\n<td width=\"558\"><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">14.20-15.20<\/span><\/td>\n<td width=\"558\"><span style=\"color: #808080;\">Industry Session supported by a grant from Alfasigma<\/span><\/p>\n<p><span style=\"color: #808080;\"><strong>CVD: Beyond Signs and Symptoms. Therapeutic Advances<\/strong><\/span><\/p>\n<p><span style=\"color: #808080;\"><em>Chair: Armando Mansilha (Portugal), Jawed Fareed (USA)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">14.20<\/span><\/td>\n<td width=\"558\"><span style=\"color: #808080;\">CVD. A complex disorder. <em>Andrew Nicolaides (Cyprus)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">14.40<\/span><\/td>\n<td width=\"558\"><span style=\"color: #808080;\">Underlying factors in CVD evolution. <em>Ferdinando Mannello (Italy)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">15.00<\/span><\/td>\n<td width=\"558\"><span style=\"color: #808080;\">Sulodexide for signs, symptoms and beyond. <em>Tomasz Urbanek (Poland)<\/em><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong><span style=\"color: #800000;\">FRIDAY 29 JUNE 2018<\/span><\/strong><\/p>\n<table style=\"height: 447px;\" width=\"672\">\n<tbody>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.00-12.00<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">Industry Session supported by a grant from Servier<\/span><br \/>\n<span style=\"color: #808080;\"><strong>Burden and Suffering in Chronic Venous Disease<\/strong><\/span><br \/>\n<em><span style=\"color: #808080;\">Chair: Nicos Labropoulos (USA), Andrew Nicolaides (Cyprus)<\/span><\/em><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.00<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">Introduction. <em>Nicos Labropoulos (USA)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.03<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">Real world evidence: The seriousness of chronic venous disease.<em> Alun H Davies (UK)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.18<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">How does chronic venous disease progress from the first symptoms to the advanced stages? <em>Nicos Labropoulos (USA)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.33<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">MPFF for patients suffering from chronic venous disease: New evidence. <em>J-H Ulloa (Colombia)<\/em><\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.48<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">Discussion<\/span><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;\" width=\"119\"><span style=\"color: #800000;\">11.58<\/span><\/td>\n<td width=\"528\"><span style=\"color: #808080;\">Concluding remarks. <em>Andrew Nicolaides (Cyprus)<\/em><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Industry Sponsored Sessions &nbsp; Tripartite Meeting 19th Meeting of the European Venous Forum 9th Annual Meeting of the Balkan Venous Forum Hellenic Phlebological Society Summit Olympia Hall, Royal Olympic Hotel, Athens, Greece 28-30 June 2018 &nbsp; THURSDAY 28 JUNE 2018 11.00-12.00 Industry Session supported by a grant from Pierre Fabre \u2026 <a class=\"continue-reading-link\" href=\"https:\/\/europeanvenousforum.org\/index.php\/19th-evf-athens-industry-symposia\/\"> Continue reading <span class=\"meta-nav\">&rarr; <\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-onecolumn.php","meta":{"_exactmetrics_skip_tracking":false,"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-4471","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/4471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/comments?post=4471"}],"version-history":[{"count":2,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/4471\/revisions"}],"predecessor-version":[{"id":4493,"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/pages\/4471\/revisions\/4493"}],"wp:attachment":[{"href":"https:\/\/europeanvenousforum.org\/index.php\/wp-json\/wp\/v2\/media?parent=4471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}